Chronic Lymphocytic Leukemia | Specialty

Using Ibrutinib in Chronic Lymphocytic Leukemia

January 19th 2016

Small-Molecule Inhibitors: Ibrutinib in CLL

January 19th 2016

The Role of Ofatumumab in the Treatment of CLL

January 19th 2016

CD-20 Antibodies in Chronic Lymphocytic Leukemia

January 19th 2016

Chemoimmunotherapy in Chronic Lymphocytic Leukemia

January 19th 2016

The Value of CT Scans in Chronic Lymphocytic Leukemia

January 19th 2016

Clinical Objectives in Chronic Lymphocytic Leukemia Treatment

January 19th 2016

Front-Line Chemoimmunotherapy in CLL

January 19th 2016

Detecting Chromosomal Abnormalities in CLL

January 19th 2016

Prognostic Factors and the Impact of New Therapies

January 19th 2016

Ublituximab Is Combined With Ibrutinib in High-Risk CLL Study

January 13th 2016

Researchers are combining the novel CD20-targeting agent ublituximab (TG-1101) with ibrutinib to determine whether the regimen can improve outcomes in CLL, particularly for patients whose disease has high-risk features.

FDA Grants Venetoclax Priority Review in Second-Line CLL

January 12th 2016

The FDA has assigned a priority review to venetoclax for use in adults with chronic lymphocytic leukemia, including patients with a 17p deletion, following at least 1 prior therapy.

Byrd on Promise of Acalabrutinib in CLL

December 21st 2015

John C. Byrd, MD, discusses the second-generation BTK inhibitor acalabrutinib, which had a 95% response rate in patients with relapsed/refractory chronic lymphocytic leukemia.

Venetoclax Improves Outlook for del17p Patients With CLL

December 18th 2015

Stephan Stilgenbauer, MD, discusses the significance of a clinical trial and the impact venetoclax could have on patients with CLL who harbor a 17p deletion.

Obinutuzumab/Venetoclax Combo Highly Effective in CLL

December 18th 2015

Treatment with the combination of the CD20 inhibitor obinutuzumab and the BCL-2 inhibitor venetoclax was tolerable and demonstrated promising signs of efficacy for elderly patients with previously untreated chronic lymphocytic leukemia and comorbidities.

Dr. Sharman on Entospletinib in Patients With CLL

December 18th 2015

Jeff Sharman, MD, director of Research with Willamette Valley Cancer Institute and Research Center, medical director of Hematology Research for The US Oncology Network, discusses clinical activity of entospletinib in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who were previously treated with a B-cell receptor pathway signaling inhibitor.

FDA Approves Bendamustine Hydrochloride for CLL, NHL

December 9th 2015

The FDA has approved a rapid infusion formulation of bendamustine under the trade name Bendeka for the treatment of patients with chronic lymphocytic leukemia or indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Dr. Kipps on Ibrutinib Versus Chlorambucil in Treatment-Naïve CLL/SLL

December 8th 2015

Thomas J. Kipps, MD, PhD, deputy director of Research, Moores University of California, San Diego Cancer Center, professor of Medicine, University of California San Diego, School of Medicine, discusses results of the RESONATE-2 study, which compared ibrutinib versus chlorambucil in elderly patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

No Safety Concerns in Trial of Ibrutinib to Early-Stage CLL

December 8th 2015

Preliminary data from an ongoing clinical trial suggest ibrutinib has an acceptable safety profile when used to prevent disease progression in patients with asymptomatic, early-stage chronic lymphocytic leukemia.

Next-Generation BTK Inhibitor Taking on Ibrutinib in CLL

December 8th 2015

Acalabrutinib has demonstrated a 95% response rate and durable remissions with a favorable safety profile in a phase I/II study for patients with chronic lymphocytic leukemia.